BOTULINUM NEUROTOXIN B IMMUNE FAB2
BOTULINUM NEUROTOXIN B IMMUNE FAB2 Uses, Dosage, Side Effects, Food Interaction and all others data.
BOTULINUM NEUROTOXIN B IMMUNE FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.
BOTULINUM NEUROTOXIN B IMMUNE FAB2 binds to botulinum toxin serotype B to prevent toxicity [FDA Label].
| Trade Name | BOTULINUM NEUROTOXIN B IMMUNE FAB2 |
| Generic | Equine Botulinum Neurotoxin B Immune FAB2 |
| Equine Botulinum Neurotoxin B Immune FAB2 Other Names | Botulinum Neurotoxin B immune FAB2 (equine), BOTULINUM NEUROTOXIN B IMMUNE FAB2, EQUINE |
| Type | |
| Protein binding | There is no protein binding data available. |
| Groups | Approved, Experimental, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
BOTULINUM NEUROTOXIN B IMMUNE FAB2 is a mixture of antibodies used to treat documented or suspected botulinum toxin exposure.
BOTULINUM NEUROTOXIN B IMMUNE FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype B in adults and pediatric patients [FDA Label].
BOTULINUM NEUROTOXIN B IMMUNE FAB2 is also used to associated treatment for these conditions: Symptomatic Botulism, Symptomatic Botulism caused by Clostridium botulinum serotype B
How BOTULINUM NEUROTOXIN B IMMUNE FAB2 works
BOTULINUM NEUROTOXIN B IMMUNE FAB2 is a mix of polyclonal antibodies for Botulinum toxin type B [FDA Label]. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.
Toxicity
BOTULINUM NEUROTOXIN B IMMUNE FAB2 may produce anaphylaxis or anaphylactoid reactions particularly in patients who have previously been exposed to equine-derived antivenom or antitoxins or patient with preexisting hypersensitivity to horses, asthma, or hay fever [FDA Label]. Serum sickness reactions may present 10-21 days after infusion. Various infusion reactions may occur dependent on the rate of infusion. These include chills, fever, headaches, nausea, and vomiting. Arthralgia, myalgia, and vasovagal reactions may also occur independently of infusion rate. Because the antibodies are derived from equine plasma there is a risk of infectious disease transmission although this is controlled through manufacturing processes.
Volume of Distribution
BOTULINUM NEUROTOXIN B IMMUNE FAB2 was found to have a mean Vd of 9.607 L after administration of one vial and 14.865 L after two vials [FDA Label].
Elimination Route
Administration of one vial of containing at least 3300 Units produced a mean Cmax of 1.90 Units/mL. Administration of two vials produced a mean Cmax of 4.28 Units/mL [FDA Label].
Half Life
BOTULINUM NEUROTOXIN B IMMUNE FAB2 was observed to have a mean half life of 34.2 h after administration of one vial and 57.1 h after two vials [FDA Label].
Clearance
BOTULINUM NEUROTOXIN B IMMUNE FAB2 was observed to have a mean clearance rate of 196 mL/h after administration of one vial and 181 mL/h after two.
Elimination Route
No data is available on excretion of BOTULINUM NEUROTOXIN B IMMUNE FAB2.
Innovators Monograph
You find simplified version here BOTULINUM NEUROTOXIN B IMMUNE FAB2
